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Background
Each year, thousands of individuals are diagnosed with
breast cancer. If detected early, the survival rate is close
to 90%; however, that rate drops to around 4% if the
breast cancer metastasizes. Breast cancer cells often and
typically metastasize to long bones, such as femur and
tibia. In long bones are large, multinucleated cells
known as megakaryocytes, which produce platelets.
Many cancer patients display an increase in platelet pro-
duction; this platelet increase leads to thromboembo-
lism, which is the leading cause of death for cancer
victims. Increased platelet production may be due in
part to an increase in megakaryopoiesis. The primary
aim of this research is to determine the presence of
mature, von Willebrand Factor-expressing megakaryo-
cytes in mice injected with cancer cells, either intracar-
dially or in the mammary glands. The secondary aim is
to determine the presence of cancer cells (GFP+) in the
bone marrow, a clear indication of metastasis.
Methods
Athymic mice were intracardially or mammary gland
injected with cancerous human MDA-MB-231 human
metastatic breast cancer cells stably transfected with a
marker protein (green fluorescent protein or GFP). The
intracardiac injection normally leads to bone metastasis,
while the mammary gland injection leads to growth of
the tumor in the mammary gland with little or no
metastasis. The mice were sacrificed on a time course.
The long bones of the mice were fixed and sectioned
for both immunohistochemical (IHC) and hematoxylin
& Eosin (H&E) staining. The avidin-biotin complex IHC
was carried out with an antibody to von Willebrand
Factor, which is expressed by megakaryocytes. H&E
allows identification of megakaryocytes based on size
and morphology.
Results
Femurs from flank injected mice sacrificed 3 – 4 weeks
post injection showed no evidence of MDA-MB-231
breast cancer cells. At two weeks post injection versus
three weeks post injection, VWF+ MKs in tibia from
mice intracardially injected with PBS (control) and
MDA-MB-231 cells were significantly lower than MDA-
MB-231-BRMS cells. Given that BRMS-1 is a transcrip-
tion factor and metastasis suppressor, it is possible that
over time it influences the down-regulation of
megakaryopoiesis.
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